Weitz Investment Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59.5M | Sell |
121,000
-13,950
| -10% | -$7.57M | 4.15% | 9 |
|
|
2025
Q4 | $78.2M | Sell |
134,950
-15,500
| -10% | -$8.77M | 4.64% | 6 |
|
|
2025
Q3 | $73M | Hold |
150,450
| – | – | 3.96% | 9 |
|
|
2025
Q2 | $61M | Buy |
150,450
+24,300
| +19% | +$10.2M | 3.28% | 11 |
|
|
2025
Q1 | $62.8M | Buy |
126,150
+5,950
| +5% | +$3.22M | 3.33% | 10 |
|
|
2024
Q4 | $62.5M | Hold |
120,200
| – | – | 3.22% | 12 |
|
|
2024
Q3 | $74.4M | Sell |
120,200
-5,000
| -4% | -$2.96M | 3.67% | 8 |
|
|
2024
Q2 | $69.2M | Hold |
125,200
| – | – | 3.63% | 8 |
|
|
2024
Q1 | $72.8M | Buy |
125,200
+120
| +0.1% | +$67.3K | 3.67% | 8 |
|
|
2023
Q4 | $66.4M | Hold |
125,080
| – | – | 3.5% | 8 |
|
|
2023
Q3 | $63.3M | Buy |
125,080
+21,380
| +21% | +$11.4M | 3.48% | 8 |
|
|
2023
Q2 | $54.1M | Buy |
103,700
+35,740
| +53% | +$19.3M | 2.88% | 14 |
|
|
2023
Q1 | $39.2M | Hold |
67,960
| – | – | 2.26% | 20 |
|
|
2022
Q4 | $37.4M | Sell |
67,960
-5,000
| -7% | -$2.65M | 2.12% | 20 |
|
|
2022
Q3 | $37M | Sell |
72,960
-5,382
| -7% | -$3.01M | 2.18% | 20 |
|
|
2022
Q2 | $42.6M | Hold |
78,342
| – | – | 2.22% | 17 |
|
|
2022
Q1 | $46.3M | Hold |
78,342
| – | – | 2.05% | 19 |
|
|
2021
Q4 | $52.3M | Sell |
78,342
-4,658
| -6% | -$2.91M | 2.1% | 18 |
|
|
2021
Q3 | $47.4M | Hold |
83,000
| – | – | 1.99% | 19 |
|
|
2021
Q2 | $41.9M | Hold |
83,000
| – | – | 1.77% | 20 |
|
|
2021
Q1 | $37.9M | Buy |
83,000
+1,500
| +2% | +$716K | 1.67% | 20 |
|
|
2020
Q4 | $38M | Sell |
81,500
-13,500
| -14% | -$6.33M | 1.62% | 20 |
|
|
2020
Q3 | $41.9M | Sell |
95,000
-15,000
| -14% | -$6.2M | 1.97% | 18 |
|
|
2020
Q2 | $39.9M | Hold |
110,000
| – | – | 1.98% | 19 |
|
|
2020
Q1 | $31.2M | Hold |
110,000
| – | – | 1.66% | 21 |
|
|
2019
Q4 | $35.7M | Hold |
110,000
| – | – | 1.4% | 25 |
|
|
2019
Q3 | $32M | Hold |
110,000
| – | – | 1.3% | 23 |
|
|
2019
Q2 | $32.3M | Buy |
110,000
+5,000
| +5% | +$1.38M | 1.28% | 27 |
|
|
2019
Q1 | $28.7M | Sell |
105,000
-873
| -0.8% | -$217K | 1.19% | 30 |
|
|
2018
Q4 | $23.7M | Sell |
105,873
-10,051
| -9% | -$2.36M | 1.09% | 30 |
|
|
2018
Q3 | $28.3M | Sell |
115,924
-15,500
| -12% | -$3.57M | 1.15% | 26 |
|
|
2018
Q2 | $27.2M | Sell |
131,424
-157
| -0.1% | -$33.3K | 1.16% | 28 |
|
|
2018
Q1 | $27.2M | Sell |
131,581
-144
| -0.1% | -$30.2K | 1.15% | 25 |
|
|
2017
Q4 | $25M | Hold |
131,725
| – | – | 1.04% | 28 |
|
|
2017
Q3 | $24.9M | Buy |
131,725
+180
| +0.1% | +$32.6K | 1.02% | 29 |
|
|
2017
Q2 | $23M | Sell |
131,545
-4,000
| -3% | -$672K | 0.99% | 30 |
|
|
2017
Q1 | $20.8M | Buy |
135,545
+3,385
| +3% | +$517K | 0.86% | 34 |
|
|
2016
Q4 | $18.6M | Buy |
+132,160
| New | +$19.5M | 0.74% | 36 |
|
Other funds holding TMO
VCM
Weitz Investment Management's TMO Position: Q1 2026 in Review
Weitz Investment Management reduced its Thermo Fisher Scientific (TMO) stake by 10% in Q1 2026, selling an estimated $7.57M and leaving 121,000 shares worth $59.5M. The position accounts for 4.15% of the portfolio, ranked #9.
Weitz Investment Management first reported a position in TMO in Q4 2016 and has held it in 38 quarters since. The position peaked at $78.2M in Q4 2025. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Weitz Investment Management held 121,000 shares of Thermo Fisher Scientific worth $59.5M as of Q1 2026.
- Weitz Investment Management sold 13,950 Thermo Fisher Scientific shares in Q1 2026, an estimated $7.57M.
- Thermo Fisher Scientific made up 4.15% of Weitz Investment Management's portfolio in Q1 2026, its #9 holding.
- Weitz Investment Management first reported a position in Thermo Fisher Scientific in Q4 2016 and has held it in 38 quarters since.
- Weitz Investment Management's Thermo Fisher Scientific position peaked at $78.2M in Q4 2025.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Weitz Investment Management's 13F filing for Q1 2026, filed 14 May 2026.